A killer combination that must be stopped
Int J Tuberc Lung Dis
.
2015 Aug;19(8):877-8.
doi: 10.5588/ijtld.15.0458.
Authors
Ramnath Subbaraman
1
,
Madhukar Pai
2
Affiliations
1
Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
2
McGill International TB Centre, McGill University, Montreal, Canada.
PMID:
26162350
PMCID:
PMC4503371
DOI:
10.5588/ijtld.15.0458
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antitubercular Agents / therapeutic use*
HIV Infections / epidemiology*
Humans
Tuberculosis, Multidrug-Resistant / drug therapy*
Substances
Antitubercular Agents
Grants and funding
R25 TW009338/TW/FIC NIH HHS/United States
T32 AI007433/AI/NIAID NIH HHS/United States